Response to First Course of Intensified Immunosuppression in Genetically Stratified Steroid Resistant Nephrotic Syndrome
Authors:
- Anna E. MasonAMAnna E. Mason
- Ethan S. SenESEthan S. Sen
- Agnieszka BierzynskaABAgnieszka Bierzynska
- Olivia BoyerOBOlivia Boyer
- Gavin I. WelshGWGavin I. Welsh
- Moin A. SaleemMSMoin A. Saleem
- on behalf of the UK RaDaR/NephroS StudyOSon behalf of the UK RaDaR/NephroS Study
- 21 April 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 15 (7) , 983-994
Abstract
Background and objectives: Intensified immunosuppression in steroid-resistant nephrotic syndrome is broadly applied, with disparate outcomes. This review of patients from the United Kingdom National Study of Nephrotic Syndrome cohort aimed to improve disease stratification by determining, in comprehensively genetically screened patients with steroid-resistant nephrotic syndrome, if there is an association between response to initial intensified immunosuppression and disease progression and/or post-transplant recurrence. Design, setting, participants, & measurements: Pediatric patients with steroid-resistant nephrotic syndrome were recruited via the UK National Registry of Rare Kidney Diseases. All patients were whole-genome sequenced, whole-exome sequenced, or steroid-resistant nephrotic syndrome gene-panel sequenced. Complete response or partial response within 6 months of starting intensified immunosuppression was ascertained using laboratory data. Response to intensified immunosuppression and outcomes were analyzed according to genetic testing results, pattern of steroid resistance, and first biopsy findings. Results: Of 271 patients, 178 (92 males, median onset age 4.7 years) received intensified immunosuppression with response available. A total of 4% of patients with monogenic disease showed complete response, compared with 25% of genetic-testing-negative patients (P=0.02). None of the former recurred post-transplantation. In genetic-testing-negative patients, 97% with complete response to first intensified immunosuppression did not progress, whereas 44% of nonresponders developed kidney failure with 73% recurrence post-transplant. Secondary steroid resistance had a higher complete response rate than primary/presumed resistance (43% versus 23%; P=0.001). The highest complete response rate in secondary steroid resistance was to rituximab (64%). Biopsy results showed no correlation with intensified immunosuppression response or outcome. Conclusions: Patients with monogenic steroid-resistant nephrotic syndrome had a poor therapeutic response and no post-transplant recurrence. In genetic-testing-negative patients, there was an association between response to first intensified immunosuppression and long-term outcome. Patients with complete response rarely progressed to kidney failure, whereas nonresponders had poor kidney survival and a high post-transplant recurrence rate. Patients with secondary steroid resistance were more likely to respond, particularly to rituximab.Keywords
Funding Information
- University of Bristol (204813/Z/16/Z (to A.E.M))
- Medical Research Council (MRC/R013942/1 (to M.A.S))
- Kidney Research UK (PDF_005_20171124 (to A.B))
- Medical Research Council (MR/P024297/1 (to M.A.S))
- National Institute for Health and Care Research (To E.S.S)
- Nephrotic Syndrome Trust (To M.A.S)
- Wellcome (204813/Z/16/Z (to A.E.M))
This publication has 46 references indexed in Scilit:
- Survey of rituximab treatment for childhood-onset refractory nephrotic syndromePediatric Nephrology, 2012
- Rituximab in Children with Resistant Idiopathic Nephrotic SyndromeJournal of the American Society of Nephrology, 2012
- The podocyte as a target: cyclosporin A in the management of the nephrotic syndrome caused by WT1 mutationsEuropean Journal of Pediatrics, 2011
- Efficacy and Safety of Treatment with Rituximab for Difficult Steroid-Resistant and -Dependent Nephrotic SyndromeClinical Journal of the American Society of Nephrology, 2010
- Immunosuppression and Renal Outcome in Congenital and Pediatric Steroid-Resistant Nephrotic SyndromeClinical Journal of the American Society of Nephrology, 2010
- Effect of cyclosporin A on proteinuria in the course of glomerulopathy associated with WT1 mutationsEuropean Journal of Pediatrics, 2010
- Rituximab for refractory focal segmental glomerulosclerosisPediatric Nephrology, 2007
- Recurrence of nephrotic syndrome/focal segmental glomerulosclerosis following renal transplantation in childrenPediatric Nephrology, 2007
- Altered activity of plasma hemopexin in patients with minimal change disease in relapsePediatric Nephrology, 2005
- Treatment of childhood steroid-resistant idiopathic nephrosis with a combination of cyclosporine and prednisoneThe Journal of Pediatrics, 1994